DelveInsight’s, “Alopecia Areata Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drug profiles, including Alopecia Areata clinical trials and nonclinical stage products. It also covers the Alopecia Areata therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Alopecia Areata Pipeline treatment landscape of the report, click here @ Alopecia Areata Pipeline Outlook

 

Key Takeaways from the Alopecia Areata Pipeline Report

• DelveInsight’s Alopecia Areata Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Alopecia Areata.
• The leading Alopecia Areata Companies include Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma, and others
• Promising Alopecia Areata Pipeline Therapies include 5% Minoxidil Topical Foam, Dutasteride, CTP-543, 8 mg BID, SHR0302, Jaktinib, Baricitinib, and others.
• On July 2023, Pfizer announced a study of phase 2 clinical trials for Etrasimod. The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams [mg] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).
• On July 2023, Eli Lilly and Company announced a study of phase 3 clinical trials for Baricitinib. The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

 

For further information, refer to the detailed Alopecia Areata Unmet Needs, Alopecia Areata Market Drivers, and Alopecia Areata Market Barriers, click here for Alopecia Areata Ongoing Clinical Trial Analysis

 

Alopecia Areata Overview

Alopecia areata (AA) is a form of alopecia that impacts hair follicles, nails, and rarely, the retinal pigment epithelium. It typically presents with round patches and is a type of non-scarring hair loss. A significant feature of the hair follicle is its relative immune privilege, this mainly established by suppression of surface molecules required for presenting auto antigens to CD8+ T lymphocytes (i.e., MHC class I) and by the generation of an inhibitory local signaling environment.

 

Alopecia Areata Emerging Drugs Profile

 

• Deuruxolitinib: Concert Pharmaceuticals

Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.

 

• EQ101: Equillium

EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.

 

• MAX 40070: Maxinovel Pharmaceuticals

MAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.

 

Request a sample and discover the recent advances in Alopecia Areata Ongoing Clinical Trial Analysis and Medications, click here @ Alopecia Areata Treatment Landscape

 

Alopecia Areata Pipeline Therapeutics Assessment

There are approx. 18+ Alopecia Areata companies which are developing the Alopecia Areata therapies. The Alopecia Areata companies which have their Alopecia Areata drug candidates in the most advanced stage, i.e. phase III include, Concert Pharmaceuticals.

 

Dive deep into rich insights for drugs for Alopecia Areata Market Drivers and Alopecia Areata Market Barriers, click here @ Alopecia Areata Unmet Needs and Analyst Views

 

Scope of the Alopecia Areata Pipeline Report

• Coverage- Global
• Alopecia Areata Companies- Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma, and others
• Alopecia Areata Pipeline Therapies- 5% Minoxidil Topical Foam, Dutasteride, CTP-543, 8 mg BID, SHR0302, Jaktinib, Baricitinib, and others.
• Alopecia Areata Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Alopecia Areata Mergers and acquisitions, Alopecia Areata Licensing Activities @ Alopecia Areata Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Alopecia Areata: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Alopecia Areata– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Deuruxolitinib: Concert Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. EQ101: Equillium
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MAX 40070: Maxinovel Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Alopecia Areata Key Companies
21. Alopecia Areata Key Products
22. Alopecia Areata- Unmet Needs
23. Alopecia Areata- Market Drivers and Barriers
24. Alopecia Areata- Future Perspectives and Conclusion
25. Alopecia Areata Analyst Views
26. Alopecia Areata Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market